Interestingly, GPR107 expression was correlated with SST5TMD4 but not with SST5, In1-ghrelin or AR-v7 expression in the more aggressive cohort of PCa samples (Cohort 2, Figure S2), which reinforces the idea of a role for GPR107 as potential therapeutic target in PCa, in that we have recently reported that SST5TMD4 is a key pathophysiological component in this cancer type [11,53]. The gene discussed is SSTR5; the disease is posterior cortical atrophy.